Rentschler Biotechnologie GmbH, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, has opened a new single-use bioreactor at its site in Laupheim, Germany with a capacity of 2,000 liters.
 
Rentschler also recently expanded its cGMP manufacturing capacity putting into operation a Twin system with two 3,000 liter stainless steel bioreactors.
 
Rentschler now has two 1,000 liter and two 2,000 liter single-use manufacturing systems available. This enables the complete manufacturing of recombinant proteins in single-use bioreactors, also for late stage clinical development and market supply of biopharmaceuticals.
 
“Only a few weeks after putting into operation our Twin system, Rentschler again is expanding its manufacturing capacity with this new 2,000 liter single-use bioreactor. This capacity expansion will enable us to meet the continuous growth in international business,” said Dr. Frank Mathias, chief executive officer of Rentschler Biotechnologie GmbH.”In the future, providing both, single-use and stainless steel technologies, will continue to play an important role and enable greater flexibility – also for our clients. We align our goals with our clients’ objectives.”
 
To support the capacity expansion at its site in Laupheim, Rentschler is looking to hire a variety of skilled employees, including process engineers and laboratory technicians in bioprocess development and manufacturing as well as GMP (Good Manufacturing Practices) experts.